Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2016 on request of the Sponsor.
On 6 December 2012, orphan designation (EU/3/12/1081) was granted by the European Commission to B. Braun Melsungen AG, Germany, for triheptanoin for the treatment of very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
- What is very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency?
Very-long-chain 3-hydroxyacyl-CoA-dehydrogenase (VLCAD) deficiency is an inherited disease caused by the lack of an enzyme called VLCAD. VLCAD is one of the enzymes needed by the mitochondria (the energy-producing components within cells) to break down certain long fatty acids in order to generate energy. If this enzyme is not present, cells cannot function normally, causing a wide range of signs and symptoms including tiredness, hypoglycaemia (low blood sugar levels), muscle wasting and damage to the heart.
The condition is chronically debilitating and life-threatening, particularly as it causes damage to the heart.
- What is the estimated number of patients affected by the condition?
At the time of designation, VLCAD deficiency affected not more than 0.32 in 10,000 people in the European Union (EU)*. This is equivalent to a total of not more than 16,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 509,000,000 (Eurostat 2012).
- What treatments are available?
At the time of orphan designation, no satisfactory method had been authorised in the European Union for the treatment of VLCAD deficiency. Treatment of patients primarily involved restriction of dietary fat to less than 30% of the total calories and the substitution of long-chain fatty acids with medium-chain fatty acids. However, these dietary regimens were of unproven value or only partially successful.
- How is this medicine expected to work?
Triheptanoin is a synthetic (artificially produced) fat, which is broken down in the liver into substances that can be used to generate energy without the need for VLCAD. By bypassing the need for VLCAD, this medicine is expected to restore the normal energy generation and ultimately improve the overall outcome of the patients.
- What is the stage of development of this medicine?
At the time of submission of the application for orphan designation, the evaluation of the effects of triheptanoin in experimental models was ongoing.
At the time of submission of the application for orphan designation, no clinical trials with triheptanoin in patients with VLCAD deficiency had been started.
At the time of submission, triheptanoin was not authorised anywhere in the EU for VLCAD deficiency. Orphan designation of triheptanoin had been granted in the United States for fatty-acid-oxidation disorders.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 7 November 2012 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/12/1081 : Public summary of opinion on orphan designation: Triheptanoin for the treatment of very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency||(English only)||25/01/2013||12/08/2016|
|Disease/condition||Treatment of very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency|
|Date of decision||06/12/2012|
|Orphan decision number||EU/3/12/1081|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details
B. Braun Melsungen AG
Tel. +49 56 61 710
Fax +49 56 61 71 2950
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.